Clear All
754 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Thalidomide Thalomid 50 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Thalidomide Thalomid 100 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
J9300 Gemtuzumab ozogamicin Mylotarg 5 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2002 In Use
C9146 Mirvetuximab soravtansine Elahere 1mg Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 No 2022 Mar 17, 2023 Jul 11, 2023 No Longer Used
J9350 Mosunetuzumab-axgb Lunsumio 1mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2022 Jul 11, 2023 In Use
J9317 Sacituzumab govitecan-hziy Trodelvy 2.5mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Jan 1, 2021 In Use
C9066 Sacituzumab govitecan-hziy Trodelvy 10mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Oct 1, 2020 Jan 1, 2021 In Use
Q5123 Rituximab-arrx Riabni 10mg Immunotherapy Monoclonal Antibody CD20 No 2021 Jul 23, 2021 In Use
Q2043 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 Jul 1, 2011 In Use
S0177 Levamisole Ergamisol 50 mg Immunotherapy Antiinfective Agent antihelminitic Yes 1990 2000 Jan 1, 2002 In Use
J9354 Ado-Trastuzumab Emtansine Kadcyla 1mg Immunotherapy Drug Antibody Conjugate HER2 No 2013 Jan 1, 2014 In Use
J9355 Trastuzumab Herceptin 10 mg Immunotherapy Monoclonal Antibody HER2 No 1998 Jan 1, 2000 In Use
J9361 Efbemalenograstim alfa-vuxw Ryzneuta 0.5mg Immunotherapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2023 Jun 10, 2024 In Use
C9118 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct 1, 2002 Dec 31, 2002 No Longer Used
C9069 Belantamab mafodotin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Jan 1, 2021 No Longer Used
Q5114 Trastuzumab-dkst Ogivri 10mg Immunotherapy Monoclonal Antibody HER2 No 2017 Jul 1, 2019 In Use
NA Dostarlimab Jemperli 50mg Immunotherapy Checkpoint Inhibitor PD-1 Yes 2021 In Use
NA Imiquimod Aldara 5% Immunotherapy Immunomodulator Retinoic Acid Derivative No 1997 In Use
C9453 Nivolumab Opdivo 1 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2014 Jul 1, 2015 In Use
C9273 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 Oct 1, 2010 Jun 30, 2011 No Longer Used
J9227 Isatuximab-irtc Sarclisa 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Oct 1, 2020 In Use
Q2057 Afamitresgene autoleucel Tecelra per therapeutic dose Immunotherapy T Cell Receptor (TCR) MAGE-A4 No 2024 Mar 26, 2025 In Use
C9174 Datopotamab Deruxtecan Datroway 1mg Immunotherapy Drug Antibody Conjugate Topoisomerase I No 2025 May 13, 2025 In Use
NA Lenalidomide Revlimid 10 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2005 In Use
J9348 Naxitamab Danyelva 1mg Immunotherapy Monoclonal Antibody GD2 No 2020 Jul 23, 2021 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.